跳至主要内容
临床试验/CTRI/2019/05/018966
CTRI/2019/05/018966尚未招募2 期

A Double Blind Randomised Controlled trial comparing Lactulose plus Rifaximin with Lactulose plus Rifaximin plus L-Ornithine L- Aspartate in treatment of Overt Hepatic Encephalopathy(Grade III-Grade IV) in patients with cirrhosis

Department of Gastroenterology G B Pant Hospital0 个研究点目标入组 0 人开始时间: 待定最近更新:

试验速览

阶段
2 期
状态
尚未招募
发起方

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional

入排标准

入选标准

  • 1. Age of patients 18-70 years.
  • 2. Hepatic cirrhosis based on clinical, biochemical, radiological and/or histological data
  • 3. Patients with overt acute grade 3 and 4 HE, according to the West Haven criteria, with or without precipitating factors

排除标准

  • 1.Acute on chronic liver failure
  • 2.Hepatocellular carcinoma
  • 3.Wilsonâ??s disease
  • 4.Advanced cardiac or pulmonary disease
  • 5.Neurologic disease (including head injury and drug intoxication) CNS active drugs.
  • 6.Pregnancy or breast feeding
  • 7.Cirrhotics with h/o HE already taking L-Ornithine â?? L â??Aspartate
  • 8.Presence of underlying chronic renal failure (serum creatinine > 1.5mg/dl)
  • 9.Psychiatric illness; patients who are on sedatives and antidepressants
  • 10.Those who do not give informed consent

研究者

发起方
Department of Gastroenterology G B Pant Hospital

相似试验